Yulong Fu
Suzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy.
Journal: Frontiers in oncology
Published: June 07, 2023
CD151 drives cancer progression depending on integrin α3β1 through EGFR signaling in non-small cell lung cancer.
Journal: Journal of experimental & clinical cancer research : CR
Published: November 30, 2020
Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy.
Journal: Frontiers in oncology
Published: October 27, 2020
Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer.
Journal: Journal of hematology & oncology
Published: September 28, 2020
KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway.
Journal: Cell death and differentiation
Published: April 12, 2020
Downregulation of KIAA1199 by miR-486-5p suppresses tumorigenesis in lung cancer.
Journal: Cancer medicine
Published: March 13, 2020
Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer without harboring EGFR T790M mutation.
Journal: Thoracic cancer
Published: March 01, 2020
EVI5 is an oncogene that regulates the proliferation and metastasis of NSCLC cells.
Journal: Journal of experimental & clinical cancer research : CR
Published: February 19, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026